NFKB1 and familial pancreatic carcinoma: These results indicate that pristimerin not only reduces constitutively active NF-κB DNA-binding activity in unstimulated conditions but also inhibits gemcitabine-induced NF-κB activation, which could be responsible for the potentiating effect of pristimerin on gemcitabine against pancreatic cancer cells.